• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sonus Pharmaceuticals to Release Second Quarter Financial Results and Hold Quarterly Conference Call August 9

Posted on: Wednesday, 2 August 2006, 21:01 CDT

Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) will release second quarter financial results on Wednesday, August 9, after the close of market. At 4:30 P.M. ET, management will host a conference call to provide a company update.

The second quarter conference call will be web cast live at 1:30 P.M. PT/4:30 P.M. ET on August 9 and can be accessed at www.sonuspharma.com/events.html. A web cast replay of the call will be available through the same link. A telephone replay will also be available from August 9, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-405-2236 or 303-590-3000 for international calls; Pass code 11067106.

About Sonus Pharmaceuticals

Headquartered near Seattle, Sonus Pharmaceuticals, Inc. is focused on the development of drugs that provide better therapeutic alternatives for cancer patients, including improved efficacy, safety and tolerability, and are more convenient to use.

The Company's lead product candidate, TOCOSOL(R) Paclitaxel, is currently in a Phase 3 pivotal study for the potential treatment of metastatic breast cancer. TOCOSOL Paclitaxel is a ready-to-use, injectable formulation of the widely prescribed anti-cancer drug, paclitaxel. In Phase 2 clinical trials, TOCOSOL Paclitaxel has shown promising anti-tumor activity in breast, lung, ovarian and bladder cancers. TOCOSOL Paclitaxel has generated encouraging safety data in the Phase 2 program and appears to be well tolerated when given weekly for extended periods. In October 2005, Sonus entered into a licensing agreement with Schering AG for the development and commercialization of TOCOSOL Paclitaxel. For additional information on the Company, including news releases, please visit www.sonuspharma.com.

Safe Harbor

Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 16, 2006 and Quarterly Report on Form 10-Q filed on May 10, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may not approve the Company's proposed New Drug Application; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Source: Business Wire

More News in this Category